专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005091716A3 ANNEXIN II AND USES THEREOF 审中-公开
公开(公告)号：WO2005091716A3
公开(公告)日：2005-10-06
申请号：PCT/IL2005/000342
申请日：2005-03-27
申请人： QUARK BIOTECH, INC. , ASTELLAS PHARMA INC. , FEINSTEIN, Elena , METT, Igor , SHTUTMAN, Michael
发明人： FEINSTEIN, Elena , METT, Igor , SHTUTMAN, Michael
IPC分类号： A61K31/70 , C07H21/04 , C07H21/02 , C12N15/00 , C12Q1/68
摘要： The present invention relates to the field of diagnosis and treatment of neurodegenerative diseases, ischemic events, and central nervous system injury, and provides compositions and methods for alleviation or reduction of the symptoms and signs associated with damaged neuronal tissues whether resulting from tissue trauma, or from chronic or acute degenerative changes. The present invention in particular relates to the discovery that the expression of Annexin II is involved in apoptosis induced by oxidative stress, and that anti-sense Annexin II RNA and Annexin II siRNA protected the cells from this apoptosis. Thus Annexin II inhibitors prevent the damage caused by said ischemic event.

2. 发明申请

WO2005041857A2 BONE MORPHOGENETIC PROTEIN (BMP) 2A AND USES THEREOF 审中-公开
标题翻译：骨形态蛋白（BMP）2A及其用途
公开(公告)号：WO2005041857A2
公开(公告)日：2005-05-12
申请号：PCT/IL2004/000924
申请日：2004-10-06
申请人： QUARK BIOTECH, INC. , FUJIWAWA PHARMACEUTICAL CO., LTD. , FEINSTEIN, Elena , METT, Igor , GORODIN, Svetlana , SHTUTMAN, Michael
发明人： FEINSTEIN, Elena , METT, Igor , GORODIN, Svetlana , SHTUTMAN, Michael
IPC分类号： A61K
CPC分类号： C12N15/1136 , C12N2310/11 , C12N2310/111 , C12N2310/14
摘要： The present invention provides compositions and methods for alleviation or reduction of the symptoms and signs associated with damaged neuronal tissues whether resulting from tissue trauma, or from chronic or acute degenerative changes. In particular, some embodiments of the present invention provide one or more pharmaceutical compositions comprising as an active ingredient a BMP2A inhibitor further comprising a pharmaceutically acceptable diluent or carrier. An additional embodiment provides a method for reducing damage to the central nervous system in a patient who has suffered an injury to the central nervous system, comprising administering to the patient a pharmaceutical composition in a dosage sufficient to reduce the damage. Yet another embodiment provides of the use of a BMP2A inhibitor for the preparation of a medicament for promoting or enhancing recovery in a patient who has suffered an injury to the central nervous system. Preferable inhibitors according to some embodiments of the invention are siRNA molecules and neutralizing antibodies. An additional embodiment provides a method for identifying a chemical compound that modulates apoptosis. Further, a process for diagnosing a neurodegenrative disease or an ischemic event in a subject is provided. The preferred methods, materials, and examples that will now be described are illustrative only and are not intended to be limiting; materials and methods similar or equivalent to those described herein can be used in practice or testing of the invention. Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.
摘要翻译：本发明提供用于缓解或减少与损伤的神经元组织相关的症状和体征的组合物和方法，无论是由组织创伤引起的，还是由慢性或急性退行性变化引起。特别地，本发明的一些实施方案提供一种或多种药物组合物，其包含作为活性成分的进一步包含药学上可接受的稀释剂或载体的BMP2A抑制剂。另外的实施方案提供了减轻对中枢神经系统损伤的患者中的中枢神经系统的损伤的方法，包括以足以减少损伤的剂量向患者施用药物组合物。另一个实施方案提供了BMP2A抑制剂用于制备用于促进或增强患有中枢神经系统损伤的患者的恢复的药物的用途。根据本发明一些实施方案的优选的抑制剂是siRNA分子和中和抗体。另外的实施方案提供了鉴定调节凋亡的化合物的方法。此外，提供了用于诊断受试者中的神经发生性疾病或缺血事件的方法。现在将要描述的优选方法，材料和实施例仅是说明性的而不是限制性的; 可以在本发明的实践或测试中使用与本文所述类似或等同的材料和方法。从以下详细描述和权利要求书中，本发明的其它特征和优点将变得显而易见。

3. 发明申请

WO2005056750A2 INVERSION-DUPLICATION OF NUCLEIC ACIDS AND LIBRARIES PREPARED THEREBY 审中-公开
标题翻译：核酸及其制备的图像的反相重复
公开(公告)号：WO2005056750A2
公开(公告)日：2005-06-23
申请号：PCT/IL2004/001114
申请日：2004-12-07
申请人： QUARK BIOTECH, INC. , FEINSTEIN, Elena , METT, Igor , SHTUTMAN, Michael
发明人： FEINSTEIN, Elena , METT, Igor , SHTUTMAN, Michael
IPC分类号： C12N
CPC分类号： C12N15/111 , C12N15/1093 , C12N15/64 , C12N15/66 , C12N2310/111 , C12N2310/14 , C12N2320/12 , C12N2330/30
摘要： The present invention concerns processes for inversion-duplication of nucleic acids, which may be used for the preparation of vectors encoding dsRNA molecules. These vectors and the processes for preparing them are useful in inhibiting the biological activity of polypeptide-encoding genes, and may be used as a tool in drug identification.
摘要翻译：本发明涉及可用于制备编码dsRNA分子的载体的核酸的反转复制方法。这些载体及其制备方法可用于抑制多肽编码基因的生物学活性，并可用作药物鉴定中的工具。

4. 发明申请

WO2004112565A3 DIAGNOSIS AND TREATMENT OF LIVER, PULMONARY AND CARDIAC FIBROSIS 审中-公开
公开(公告)号：WO2004112565A3
公开(公告)日：2004-12-29
申请号：PCT/IL2004/000565
申请日：2004-06-24
申请人： QUARK BIOTECH, INC. , MOR, Orna , FAERMAN, Alexander , FEINSTEIN, Elena
发明人： MOR, Orna , FAERMAN, Alexander , FEINSTEIN, Elena
IPC分类号： A61K38/00 , C07K1/00 , C07K14/00 , C07K17/00
摘要： This application is directed to a method for the treatment of fibrosis, preferably liver fibrosis, pulmonary fibrosis and cardiac fibrosis, in a subject in need of such treatment comprising administering to said subject an amount of an inhibitor of HNOEL-iso polypeptide sufficient to effect a substantial inhibition of the HNOEL-iso polypeptide so as to thereby treat the subject. This application is also directed to a process of obtaining a compound which inhibits human HNOEL-iso polypeptide. This application is also directed to use of a compound identified by that process in the preparation of a medicament for therapy of disease, in particular fibrosis, and to diagnostic aspects related to HNOEL-iso polypeptide.

5. 发明申请

WO2005072057A2 OLIGORIBONUCLEOTIDES AND METHODS OF USE THEREOF FOR TREATMENT OF FIBROTIC CONDITIONS AND OTHER DISEASES 审中-公开
标题翻译：用于治疗纤维性疾病和其他疾病的低分子化合物及其使用方法
公开(公告)号：WO2005072057A2
公开(公告)日：2005-08-11
申请号：PCT/IL2005/000102
申请日：2005-01-27
申请人： QUARK BIOTECH, INC. , MOR, Orna , FEINSTEIN, Elena
发明人： MOR, Orna , FEINSTEIN, Elena
IPC分类号： A61K48/00 , C07H21/04 , C07K14/705 , C07K16/18 , C07K16/40 , C12N9/10 , C12N15/113 , C12Q1/68
CPC分类号： C07H21/04 , C07K16/40 , C07K2317/21 , C07K2317/76 , C12N9/1044 , C12N15/1137 , C12N2310/111 , C12N2310/14 , C12N2310/321 , C12N2310/322 , C12Y203/02013 , C12N2310/3527 , C12N2310/3521
摘要： The invention relates to a double-stranded compound, preferably an oligoribonucleotide (siRNA), which down-regulates the expression of a human TGaseII gene at the post-transcriptional level. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from a fibrotic disease such as pulmonary, kidney and liver fibrosis or ocular, scarring comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient. The invention also relates to treatment of fibrotic and other diseases by use of antibodies to TGaseII polypeptide.
摘要翻译：本发明涉及在转录后水平下调人TGaseII基因表达的双链化合物，优选寡核糖核苷酸（siRNA）。本发明还涉及包含该化合物或能够表达寡核糖核苷酸化合物的载体和药学上可接受的载体的药物组合物。本发明还考虑了治疗患有纤维化疾病如肺，肾和肝纤维化或眼睛，瘢痕形成的患者的方法，其包括以治疗有效剂量向患者施用药物组合物，从而治疗患者。本发明还涉及通过使用TGaseII多肽的抗体来治疗纤维化和其它疾病。

6. 发明申请

WO2004112566A3 DIAGNOSIS AND TREATMENT OF NEPHROPATHY 审中-公开
公开(公告)号：WO2004112566A3
公开(公告)日：2004-12-29
申请号：PCT/IL2004/000566
申请日：2004-06-24
申请人： QUARK BIOTECH, INC. , MOR, Orna , FAERMAN, Alexander , FEINSTEIN, Elena
发明人： MOR, Orna , FAERMAN, Alexander , FEINSTEIN, Elena
IPC分类号： A61K45/00
摘要： This application is directed to a method for the treatment of nephropathy or kidney fibrosis or glomerulosclerosis or chronic renal insufficiency in a subject in need of such treatment comprising administering to said subject an amount of an inhibitor of HNOEL-iso polypeptide sufficient to effect a substantial inhibition of the HNOEL-iso polypeptide so as to thereby treat the subject. This application is also directed to a process of obtaining a compound which inhibits human HNOEL-iso polypeptide This application is also directed to use of a compound identified by that process in the preparation of a medicament for therapy of disease, in particular nephropathy, and to diagnostic aspects related to HNOEL-iso polypeptide.

7. 发明申请

WO2004112565A2 DIAGNOSIS AND TREATMENT OF LIVER, PULMONARY AND CARDIAC FIBROSIS 审中-公开
标题翻译：诊断和治疗肝，肺和心脏纤维化
公开(公告)号：WO2004112565A2
公开(公告)日：2004-12-29
申请号：PCT/IL2004/000565
申请日：2004-06-24
申请人： QUARK BIOTECH, INC. , MOR, Orna , FAERMAN, Alexander , FEINSTEIN, Elena
发明人： MOR, Orna , FAERMAN, Alexander , FEINSTEIN, Elena
IPC分类号： A61B
CPC分类号： G01N33/576 , A61K2039/505 , C07K14/47 , C07K16/18 , G01N2500/04 , G01N2800/085
摘要： This application is directed to a method for the treatment of fibrosis, preferably liver fibrosis, pulmonary fibrosis and cardiac fibrosis, in a subject in need of such treatment comprising administering to said subject an amount of an inhibitor of HNOEL-iso polypeptide sufficient to effect a substantial inhibition of the HNOEL-iso polypeptide so as to thereby treat the subject. This application is also directed to a process of obtaining a compound which inhibits human HNOEL-iso polypeptide. This application is also directed to use of a compound identified by that process in the preparation of a medicament for therapy of disease, in particular fibrosis, and to diagnostic aspects related to HNOEL-iso polypeptide.
摘要翻译：本申请涉及在需要这种治疗的受试者中治疗纤维化，优选肝纤维化，肺纤维化和心脏纤维化的方法，包括向所述受试者施用一定量的足以产生HNO- 显着抑制HNOEL-iso多肽，从而治疗受试者。本申请还涉及获得抑制人HNOEL-iso多肽的化合物的方法。本申请还涉及通过该方法鉴定的化合物在制备用于治疗疾病，特别是纤维化以及与HNOEL-iso多肽相关的诊断方面的药物中的用途。

8. 发明申请

WO2003063689A2 ISLR GENE AND ITS ASSOCIATION WITH OSTEOARTHRITIS AND OTHER BONE AND CARTILAGE DISORDERS, EXPRESSION PRODUCTS DERIVED THEREFROM, AND USES THEREOF 审中-公开
标题翻译： ISLR基因及其与骨质疏松症和其他骨质疏松症的联系，其衍生的表达产物及其用途
公开(公告)号：WO2003063689A2
公开(公告)日：2003-08-07
申请号：PCT/US2003/002666
申请日：2003-01-29
申请人： QUARK BIOTECH, INC. , SHIONOGI & CO., LTD. , SEGEV, Orit , FEINSTEIN, Elena
发明人： SEGEV, Orit , FEINSTEIN, Elena
IPC分类号： A61B
CPC分类号： G01N33/5091 , A01K2217/05 , A01K2267/035 , C07K16/22 , C07K2317/76 , C12N2830/008 , C12Q1/6883 , C12Q2600/136 , C12Q2600/158 , G01N33/5008 , G01N33/5023 , G01N33/5044 , G01N33/564 , G01N33/6893 , G01N2800/102 , G01N2800/105
摘要： The disclosure relates to the ISLR gene, and functional equivalents thereof, such as those from humans and from mice, probes therefor, tests to identify such genes, expression products of such genes, uses for such genes and expression products, e.g ., in diagnosis (for instance, risk determination), treatment, prevention, or control of osteoarthritis or rheumatoid arthritis or osteoporosis or other bone disorders or conditions or factors or processes which lead to these disorders or conditions ; and to diagnosis, treatment, prevention, or control methods or processes,. as well as compositions therefor and methods or processes for making and using such compositions, and receptors therefor and methods or processes for obtaining and using such receptors.
摘要翻译：本公开涉及ISLR基因及其功能等同物，例如来自人和小鼠的那些，其探针，用于鉴定这些基因的测试，这些基因的表达产物，这些基因和表达产物的用途，治疗，预防或控制骨关节炎或类风湿性关节炎或骨质疏松症或其他导致这些疾病或病症的骨病或其他疾病或因素或过程的诊断（例如风险确定）以及诊断，治疗，预防或控制方法或过程。以及其组合物和用于制备和使用这些组合物的方法或方法及其受体和用于获得和使用这些受体的方法或方法。

9. 发明申请

WO2006035434A3 OLIGORIBONUCLEOTIDES AND METHODS OF USE THEREOF FOR TREATMENT OF ALOPECIA, ACUTE RENAL FAILURE AND OTHER DISEASES 审中-公开
公开(公告)号：WO2006035434A3
公开(公告)日：2006-04-06
申请号：PCT/IL2005/001035
申请日：2005-09-27
申请人： QUARK BIOTECH, INC. , FEINSTEIN, Elena , ZURR, Daniel , EHRLICH, Shai
发明人： FEINSTEIN, Elena , ZURR, Daniel , EHRLICH, Shai
IPC分类号： C07H21/00 , A61K31/70
摘要： The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a human p53 gene. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from alopecia or acute renal failure or other diseases comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient. The alopecia may be induced by chemotherapy or radiotherapy, and the patient may be suffering from cancer, in particular breast cancer.

10. 发明申请

WO2003063689A3 ISLR GENE AND ITS ASSOCIATION WITH OSTEOARTHRITIS AND OTHER BONE AND CARTILAGE DISORDERS, EXPRESSION PRODUCTS DERIVED THEREFROM, AND USES THEREOF 审中-公开
公开(公告)号：WO2003063689A3
公开(公告)日：2003-08-07
申请号：PCT/US2003/002666
申请日：2003-01-29
申请人： QUARK BIOTECH, INC. , SHIONOGI & CO., LTD. , SEGEV, Orit , FEINSTEIN, Elena
发明人： SEGEV, Orit , FEINSTEIN, Elena
IPC分类号： C12Q1/00
摘要： The disclosure relates to the ISLR gene, and functional equivalents thereof, such as those from humans and from mice, probes therefor, tests to identify such genes, expression products of such genes, uses for such genes and expression products, e.g ., in diagnosis (for instance, risk determination), treatment, prevention, or control of osteoarthritis or rheumatoid arthritis or osteoporosis or other bone disorders or conditions or factors or processes which lead to these disorders or conditions ; and to diagnosis, treatment, prevention, or control methods or processes,. as well as compositions therefor and methods or processes for making and using such compositions, and receptors therefor and methods or processes for obtaining and using such receptors.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式